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ABSTRACT
ObjectiveTodeterminetheeffectivenessofincreasingthe
dietary content of soluble fibre (psyllium) or insoluble
fibre (bran) in patients with irritable bowel syndrome.
Design Randomised controlled trial.
Setting General practice.
Participants 275 patients aged 18-65 years with irritable
bowel syndrome.
Interventions 12 weeks of treatment with 10 g psyllium
(n=85), 10 g bran (n=97), or 10 g placebo (rice flour)
(n=93).
Main outcome measures The primary end point was
adequate symptom relief during at least two weeks in the
previous month, analysed after one, two, and three
months of treatment to assess both short term and
sustained effectiveness. Secondary end points included
irritable bowel syndrome symptom severity score,
severity of abdominal pain, and irritable bowel syndrome
quality of life scale.
Results The proportion of responders was significantly
greater in the psyllium group than in the placebo group
during the first month (57% v 35%; relative risk 1.60,
95% confidence interval 1.13 to 2.26) and the second
month of treatment (59% v 41%; 1.44, 1.02 to 2.06).
Bran was more effective than placebo during the third
month of treatment only (57% v 32%; 1.70, 1.12 to
2.57), but this was not statistically significant in the
worst case analysis (1.45, 0.97 to 2.16). After three
months of treatment, symptom severity in the psyllium
group was reduced by 90 points, compared with
49pointsintheplacebogroup(P=0.03)and58pointsin
the bran group (P=0.61 versus placebo). No differences
werefound withrespecttoqualityoflife.Fiftyfour(64%)
of the patients allocated to psyllium, 54 (56%) in the
bran group, and 56 (60%) in the placebo group
completed the three month treatment period. Early
dropout was most common in the bran group; the main
reason was that the symptoms of irritable bowel
syndrome worsened.
Conclusions Psyllium offers benefits in patients with
irritable bowel syndrome in primary care.
Trial registration Clinical trials NCT00189033.
INTRODUCTION
Irritable bowel syndrome is a common functional
gastrointestinal disorder characterised by recurrent
episodes of abdominal pain or discomfort associated
with an altered bowel habit, not explained by any
structural or biochemical changes in the gut.
1 The pre-
valence of irritable bowel syndrome in the population
is in the order of 10%, and approximately a quarter of
people with irritable bowel syndrome symptoms seek
medical advice.
2
Most studiesreport a female predominance, and the
reported incidence of irritable bowel syndrome in pri-
mary care is 4-13 per 1000 patients per year, less than
5% of whom are referred to hospital.
3 Irritable bowel
syndrome is a chronic recurrent condition with relap-
singsymptomsinmore thanhalfofpatients.
4 Itshould
not be diagnosed by exclusion but rather as a “posi-
tive” diagnosis. Diagnostic tools such as the Rome cri-
teria have been developed to facilitate this. The Rome
criteria are primarily designed for research purposes,
and their validity in clinical primary care is not well
established; most general practitioners do not use
them.
5-8
In the management of irritable bowel syndrome,
dietary advice is often given. Most general practi-
tioners recommend an increase in the fibre content of
thedailydiet,throughtheadditionofinsolublefibrein
the form of bran.
9 Furthermore, approximately half
of patients with irritable bowel syndrome receive
drug treatment, often including psyllium based
supplements.
10 However, pooled analyses show lim-
ited evidence that fibre actually alleviates symptoms
of irritable bowel syndrome, and insoluble fibre may
even worsen the symptoms.
11-13 Most available studies
on fibre treatment have severe methodological limita-
tions,suchasinadequateoutcomeassessmentandlack
of placebo control, and all trials were done in second-
arycare.Incontrast,mostpatientswithirritablebowel
syndrome are treated in primary care, and this patient
group may benefit more from fibre treatment than do
those in secondary care.
391415
We dida randomised placebocontrolled trialin pri-
mary care patients with irritable bowel syndrome to
1Julius Center for Health Sciences
and Primary Care, University
Medical Center Utrecht,
PO Box 85500, 3508 GA Utrecht,
Netherlands
2Department of General Practice,
Care and Public Health Research
Institute (CAPHRI), Maastricht
University, 6200 MD Maastricht,
Netherlands
3Department of Medicine and
Gastroenterology, University of
Manchester, Manchester,
M23 9LT
Correspondence to: C J Bijkerk
c.j.bijkerk-2@umcutrecht.nl
Cite this as: BMJ 2009;339:b3154
doi:10.1136/bmj.b3154
BMJ | ONLINE FIRST | bmj.com page 1 of 7assess the effectiveness of treatment with either psy-
llium or bran on symptoms and quality of life.
METHODS
Setting and participants
We recruited patients in the practices of the Utrecht
and Maastricht primary care research networks. Gen-
eral practitioners in both networks have vast experi-
ence in participating in clinical trials in primary care.
Patients aged between 18 and 65 years who had been
diagnosed as having irritable bowel syndrome in the
previous two years were selected from the medical
electronic files of the participating practices by using
the international classification of health problems in
primary care (ICPC) code D93 (irritable bowel syn-
drome) or the text words “IBS” or “spastic colon.”
16
The selected patients received an invitation signed by
their general practitioner to participate in the trial.
Non-responding patients received one reminder. In
additiontothese“prevalent”irritablebowelsyndrome
patients, patients consulting their general practitioner
with new onset irritable bowel syndrome during the
inclusion period (“incident” irritable bowel syndrome
patients) were also invited to participate.
Patientswithsymptomsofirritablebowelsyndrome
during the previous four weeks with either “definite”
irritable bowel syndrome according to the Rome II
diagnostic criteria or “probable” irritable bowel syn-
drome pragmatically diagnosed by their general prac-
titioner were eligible for inclusion.
117The box shows
theRomeIIcriteriaandthemorepragmaticdefinition
ofirritablebowelsyndromeusedinprimarycareinthe
Netherlands.Patientsinitiallydiagnosedashavingirri-
tablebowelsyndromebutfoundtohaveorganicbowel
disease in follow-up (for example, colon cancer, coe-
liacdisease,andinflammatoryboweldisease),patients
who had used fibre treatment in the previous four
weeks, those with severe psychosocial disturbance
and psychiatric disorders (panic disorder, generalised
anxietydisorder,andmooddisorder),thoseunderspe-
cialist treatment for irritable bowel syndrome in the
previous two years, and those who did not understand
the Dutch language were excluded. All patients gave
written informed consent. The inclusion period lasted
from April 2004 to October 2006.
Randomisation
Patients were randomly allocated to one of two active
treatment groups or placebo by means of a procedure
using six block random number tables. The pharmacy
of the University Medical Center Utrecht produced
the randomisation list. The practice nurse determined
the treatment allocation by drawing a sealed non-
opaque envelope, which contained instructions on
the type of trial treatment to be given to the patient.
Randomisation was done after the baseline visit and
after the patient agreed to participate and signed the
informed consent. The nurses were strictly instructed
to open the randomisation envelope only after the
baseline visit at the general practitioners’ office.
Patients were randomlyallocated to a 12 week treat-
ment regimen with 10 g psyllium (soluble fibre), 10 g
bran (insoluble fibre), or placebo (rice flour) in two
daily dosages, to be taken with meals by mixing with
food,preferablyyoghurt.Theaverageintakeofdietary
fibre in an adult Dutch population aged 25-65 years is
estimatedtobe24.0(SD6.9)g/dayor10.5(2.6)g/4.18
MJ (1000 kcal). An addition of 10 g fibre to the diet
(total dietary fibre content 30-40 g) is usually consid-
ered adequate.
18 The practice nurse delivered the diet-
ary supplements in identical containers at monthly
study visits. The study was blinded at three levels
(patient, doctor, and researchpersonnel), but the prac-
tice nurse was aware of the treatment allocated. All
participantswereinstructednottochangetheirdietary
habits and to take sufficient fluids each day.
Outcomes measures
In line with previous recommendations for outcome
assessment in research into functional gastrointestinal
disease,
1920wechosetheadequatereliefquestion(“Did
you have adequate relief of irritable bowel syndrome
related abdominal pain or discomfort in the past
week?”) as the primary outcome. This instrument is a
validated and generally accepted simple outcome
assessment for treatment of irritable bowel syndrome.
We considered both short term relief of symptoms,
particularly during periods of exacerbation of symp-
toms, and sustained, longer term effectiveness to be
relevant in evaluating the effectiveness of fibre treat-
ment. For this reason, we chose to evaluate effective-
ness on a monthly basis and defined responders as
those patients who reported adequate relief of symp-
toms during at least two out of the previous four
weeks.
21 We assessed this primary outcome after one,
two, and three months of treatment. The patients were
asked to keep a weekly diary during the 12 weeks of
treatment and to measure adherence to treatment. We
calculated the primary outcome from the weekly
assessments,whichwerecollectedatthescheduledfol-
low-up visits to the general practitioner one, two, and
three months after the baseline visit.
Definitions of irritable bowel syndrome
Rome II criteria for irritable bowel syndrome
1
 At least 12 consecutive weeks of abdominal discomfort or pain in the preceding
12 months, with at least two of the following features:
Relieved with defecation
Onset associated with change in stool frequency
Onset associated with change in stool consistency
 In the absence of structural or metabolic abnormalities to explain the symptoms
Pragmatic definition of irritable bowel syndrome
17
 Chronic gastrointestinal disorder characterised by recurrence of abdominal pain or
bloating in relation to disturbed bowel habits, for at least four weeks
 Mucus without blood in the stools, the presence of a palpable tender colon, and
discomfort during rectal examination have been proposed to support the diagnosis of
irritable bowel syndrome
 In the absence of alarm symptoms (weight loss, rectal bleeding, nocturnal symptoms,
or anaemia)
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ity of symptoms of irritable bowel syndrome, severity
of abdominal pain, and quality of life. Severity of
symptoms was assessed with the irritable bowel syn-
drome symptom severity score. This is a validated
symptom score that uses visual analogue scales to
relate five aspects of bowel dysfunction to the actual
intensity of symptoms of irritable bowel syndrome.
The severity of abdominal pain was measured by
means of the first question of this score.
22 Disease spe-
cific quality of life was monitored with the irritable
bowel syndrome quality of life scale, which comprises
30 items in nine subscales and has been validated in
various populations.
23 Fibre intake was monitored
every month during the trial with a food frequency
questionnaire including 78 items on fibre intake and
24onfluidintake.Theselfadministeredquestionnaire
isvalidatedforrankingparticipantsaccordingtointake
of dietary fibre and was adapted from the EPIC food
frequency questionnaire.
2425 The secondary outcomes
were recorded during one, two, and three months.
Adherence to the trial treatment was checked at
every visit by scrutinising the patient’s diary. Adverse
eventswererecordedfrompartBoftheirritablebowel
syndrome symptom severity scale.
22 We considered
patients to have side effects of moderate severity if
they reported the symptoms for more than half of the
time during the previous month.
As blinding is difficult in studies with fibre as the
intervention, we asked patients, after completion of
the trial, to guess which treatment they had received.
We used a strict protocol for the follow-up of patients.
We instructed the nurses to check the questionnaires
for completeness at regular visits. Patients who did not
attendweresentawrittenreminderandlatercontacted
by telephone in case of persistent non-response.
Sample size
Weconsideredaminimaldifferenceof20%inthepro-
portionof responders on the adequate reliefscale (that
is,morethantwoweeks’adequatereliefinfourweeks)
between the active treatments and placebo to be clini-
cally relevant. The placebo response was estimated at
40%.
26 We thus needed 95 patients in each treatment
arm to give the study 80% power with a type I error of
5%. We aimed to include 285 patients.
Data analysis
Statistical analyses were based on the intention to treat
principle. We calculated the proportion of responders
in the three groups and compared them at one, two,
and three months. Relative risks with 95% confidence
intervals and risk differences with 95% confidence
intervals compared with placebo were calculated. We
made similar calculations after imputing missing
valuesontheprimaryoutcome,assumingthatpatients
who did not fill in the adequate relief question in the
diary were non-responders (“worst case analysis”).
Changes in the secondary outcomes—irritable bowel
syndromesymptomseverityscore,severityofabdom-
inalpain,andirritablebowelsyndromequalityoflifeat
one,two,andthreemonthsafterthebaselinemeasure-
ments—were also compared. We assessed stability of
the treatment effect over time by using one factorial
analysis of variance for repeated measures. To correct
for possible differences in relevant baseline character-
isticsbetweenthethreegroups,wedidmultiplelogistic
regressionanalyses.Asprespecifiedinthestudyproto-
col, we did subgroup analyses of patients who fulfilled
the Rome II irritable bowel syndrome diagnostic cri-
teria and of those with constipation predominant irri-
table bowel syndrome.
RESULTS
Participants
A total of 296 patients agreed to participate in the trial:
193 patients with “prevalent” irritable bowel syndrome
and 103 with “incident” irritable bowel syndrome. For
various reasons (second thoughts, non-eligibility, or no
time), 21 patients did not attend the baseline visit. In
total, 275 patients were randomised; 85 were allocated
topsyllium,97tobran,and93toplacebo(fig1).Mostof
thepatientswerewhite(94%)andfemale(78%),andthe
mean age was 34.4 (SD 10.9) years. Irritable bowel
Patients identified in EMF with IBS in previous 2 years recruited for participation in trial (n=2100)
Responders assessed for eligibility (n=1288)
Prevalent patients eligible (n=564)
Prevalent patients consented (n=193)
Patients referred to nurse (n=296)
Incident patients with IBS consented (n=103)
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Patients excluded (n=724)*:
  No active IBS symptoms in previous 4 weeks (n=564)
  Received prescription for fibre in previous 4 weeks (n=72)
  Active treatment for anxiety and depression (n=87)
  Treated for IBS in secondary care (n=101)
Patients randomised (n=275)
Did not attended baseline visit (n=21)
Allocated to psyllium (n=85)
Did not attend visit (n=6)
Allocated to bran (n=97)
Did not attend visit (n=20)
Allocated to placebo (n=93)
Did not attend visit (n=15)
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Patients assessed (n=79)
Did not attend visit (n=13)
Patients assessed (n=77)
Did not attend visit (n=14)
Patients assessed (n=78)
Did not attend visit (n=12)
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Patients assessed (n=66)
Did not attend visit (n=12)
Patients assessed (n=63)
Did not attend visit (n=9)
Patients assessed (n=66)
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Patients assessed (n=54) Patients assessed (n=54) Patients assessed (n=56)
Did not attend visit (n=10)
Fig 1 | Flow chart of trial. No patients assigned to psyllium, bran, or placebo received different
treatment. EMF=electronic medical file; IBS=irritable bowel syndrome. *Number exceeds 724
because more than one reason could be given
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yearsin25%ofthepatients,and39%fulfilledtheRome
II criteria for irritable bowel syndrome. More than half
(56%)ofthepatientshadconstipationpredominantirri-
tablebowelsyndrome.Themeanintakeofdietaryfibre
before participation was 26.9 (SD 11.8) g/day, and
patients used on average 2.4 (1.0) l/day of fluids. At
baseline, patients allocated to psyllium reported less
severe abdominal pain associated with irritable bowel
syndrome than did those in the bran and placebo
groups.Thetreatmentgroupsdidnotdifferwithrespect
to other characteristics (table 1).
Twohundredandthirtyfour(85%)patientsattended
the second visit at one month, 195 (71%) attended the
visit at two months, and 164 (60%) attended the final
visit at the end of the three month treatment period
(fig 1). In total, 111 (40%) patients were lost to follow-
up during the treatment period: 31 (36%) in the psy-
llium group, 43 (44%) in the bran group, and 37
(40%) in the placebo group. Reasons given were non-
medical (such as moved to another city, n=15), pre-
sumed lack of benefit (n=10), symptom free (n=2),
andintoleranceoftrialtreatment(n=34;7patientsallo-
cated to psyllium, 18 patients allocated to bran, and
9 patients allocated to placebo). For the other patients,
the reason for withdrawal was unknown (n=50).
Patients who completed the trial and those lost to
follow-up did not significantly differ with respect to
demographic and disease specific characteristics (data
not shown).
Primary outcome
Rates of response (that is, more than two weeks’ ade-
quate relief per month) were significantly higher with
psyllium than with placebo during the first month of
treatment (45/79 (57%) v 27/78 (35%); relative risk
1.60, 95% confidence interval 1.13 to 2.26), with a
risk difference of 22% (95% confidence interval 7% to
38%). Thenumberneededto treatwasfour (thatis, for
every four patients who received psyllium, one
reported at least two weeks’ adequate relief of abdom-
inal pain or discomfort during one month of treat-
ment). We saw a similar positive effect during the
second month of treatment (39/66 (59%) v 27/66
(41%); relative risk 1.44, 1.02 to 2.06). During the
third month of treatment the difference between psy-
llium and placebo—25/54 (46%) v 18/56 (32%)—was
not statistically significant (relative risk 1.36, 0.90 to
2.04). Only in the third month of treatment was bran
more effective than placebo (31/54 (57%) v 18/56
(32%); relative risk 1.70, 1.12 to 2.57) (table 2).
Atbaseline,thethreetreatmentgroupswerecompar-
ablewiththeexceptionofasomewhatlowerseverityof
symptomsinthepsylliumgroup.However,adjustment
for baseline symptom severity in the multivariate logis-
ticregressionanalysisonlyincreasedthe observedben-
eficialeffect—inthefirstmonthoftreatmenttherelative
risk for adequate relief in the psyllium group versus the
placebogroup was 2.70 (1.33 to5.46).Inthe worst case
analysis (considering patients lost to follow-up as non-
responders),psylliumremainedmoreeffectivethanpla-
cebo during the first two months of treatment, but bran
was no longer superior to placebo during the third
month (1.45, 0.97 to 2.16) (table 3).
Analysisrestrictedtopatientswhofulfilled the Rome
II criteria for irritable bowel syndrome showed larger
responder rates for psyllium compared with placebo—
relative risk during the first month 1.81 (1.12 to 2.94)
compared with 1.60 (1.13 to 2.26) for all patients with
irritable bowel syndrome. A subgroup analysis of
patients with constipation dominated irritable bowel
syndrome showed comparable results—during the first
month of treatment psyllium was better than placebo
(1.65, 1.05 to 2.62). Figure 2 shows the proportion of
patients in each group with adequate relief each week.
Table 1 |Baseline characteristics. Values are numbers (percentages) unless stated otherwise
Characteristic Psyllium (n=85) Bran (n=97) Placebo (n=93)
Mean (SD) age (years) 35 (10) (n=81) 34 (12) (n=89) 35 (18) (n=86)
Female 64 (75) 74 (76) 77 (83)
White ethnicity 79 (93) 87/94 (93) 84/87 (97)
Duration of symptoms (years): (n=95) (n=88)
<2 19 (22) 31 (33) 17 (19)
2-5 27 (32) 24 (25) 18 (21)
6-10 13 (15) 17 (18) 18 (21)
>10 26 (31) 23 (24) 35 (40)
IBS according to Rome II criteria 35 (41) 39 (40) 33 (36)
IBS subtype:
Constipation 45 (53) 56 (58) 54 (58)
Diarrhoea 25 (29) 18 (19) 25 (27)
Alternating 15 (18) 23 (24) 14 (15)
IBS symptoms—mean (SD):
IBS symptomseverity score(0-500) 262 (68) (n=80) 270 (77) (n=82) 279 (70) (n=82)
Severity of abdominal pain (0-100) 43 (29) (n=82) 54 (32) (n=86) 55 (37) (n=77)
IBS quality of life scale (0-100) 72 (16) (n=77) 74 (16) (n=83) 74 (15) (n=79)
Dietary intake—mean (SD):
Fibre (g/day) 28 (12) 28 (15) (n=96) 27 (15) (n=90)
Fluids (l/day) 2.3 (1.0) 2.4 (1.0) (n=96) 2.4 (1.0) (n=91)
IBS=irritable bowel syndrome.
Table 2 |Adequate relief of abdominal pain or discomfort (at least two weeks every four
weeks): intention to treat analysis
Follow-upassessment
and treatment
Responders
(%)
Relative risk (95%
CI)
% treatment
difference(95%CI)
Number needed
to treat
Month 1
Psyllium 45/79 (57) 1.60 (1.13 to 2.26) 22 (7 to 38) 4.5
Bran 31/77 (40) 1.13 (0.81 to 1.58) 5 (−10 to 21) 16.7
Placebo 27/78 (35) NA NA NA
Month 2
Psyllium 39/66 (59) 1.44 (1.02 to 2.06) 18 (14 to 35) 5.6
Bran 32/63 (51) 1.22 (0.86 to 1.72) 10 (−7 to 27) 10.0
Placebo 27/66 (41) NA NA NA
Month 3
Psyllium 25/54 (46) 1.36 (0.90 to 2.04) 14 (−4 to 32) 7.1
Bran 31/54 (57) 1.70 (1.12 to 2.57) 25 (7 to 43) 4.0
Placebo 18/56 (32) NA NA NA
NA=not applicable.
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The reduction in severity of symptoms in the psyllium
groupwashigherthanthatintheplacebogroup,witha
significant mean reduction of 90 versus 49 points
(P=0.03)onlyafterthreemonthsoftreatment,whereas
the change in severity of symptoms in the bran group
was comparable to that in the placebo group. We
found no significant differences between the three
groups with respect to changes in the severity of
abdominal pain related to irritable bowel syndrome
or in quality of life (table 4).
Adherence
Adherencetothetrialtreatmentdidnotdifferbetween
thepsylliumandbrangroups.Patientsallocatedtopsy-
llium added on average 7.1 (SD 3.1) g/day, bringing
their total intake of dietary fibre to 35.1 (14.9) g/day.
Patients allocated to bran added on average 6.5 (3.3)
g/day and consumed 34.1 (17.2) g/day dietary fibre
in total.The fibreintake in the daily diet,as monitored
with the food frequency questionnaire, did not change
during the treatment period. Total fluid intake, on
average 2.5 (SD 0.8) l/day, did not differ between the
groups.
Adverse events
Sixty three (74%) of 85 patients in the psyllium group,
62/97 (64%) patients in the bran group, and 61/93
(66%) patients in the placebo group reported at least
one adverse event of moderate severity during the
study (table 5). Diarrhoea and constipation were the
mostcommonly reportedadverseevents.Thepropor-
tions ofpatientswith diarrhoeaand constipationin the
psylliumandbrangroupswerecomparabletothosein
theplacebogroup.Severeconstipationwasreportedin
one patient treated with bran. No serious adverse
events were reported during the study.
DISCUSSION
In this randomised trial in primary care patients with
irritablebowelsyndrome,psylliumresultedinasignif-
icantly greater proportion of patients reporting ade-
quate relief of symptoms compared with placebo
supplementation. Patients receiving psyllium also
reported a significant reduction in severity of
Table 3 |Adequate relief of abdominal pain or discomfort (at least two weeks every four
weeks): intention to treat analysis with imputation of missing data as non-responders (worst
case analysis)
Follow-up assessment
and treatment Responders (%)
Relative risk
(95% CI)
% treatment
difference
(95% CI)
Number needed
to treat
Month 1
Psyllium 45/85 (53) 1.66(1.19to2.31) 24 (10 to 38) 4.2
Bran 31/97 (32) 1.07(0.78to1.49) 3 (−10 to 16) 33.3
Placebo 27/93 (29) NA NA NA
Month 2
Psyllium 39/85 (46) 1.44(1.04to2.00) 17 (3 to 31) 5.9
Bran 32/97 (33) 1.10(0.80to1.53) 4 (−9 to 17) 25.0
Placebo 27/93 (29) NA NA NA
Month 3
Psyllium 25/85 (29) 1.32(0.91to1.95) 10 (−3 to 23) 10.0
Bran 31/97 (32) 1.45(0.97to2.16) 13 (0.3 to 25) 7.7
Placebo 18/93 (19) NA NA NA
NA=not applicable.
Table 4 |Absolute and relative change in severity of symptoms, severity of abdominal pain, and quality of life from baseline
by one, two, and three months of treatment
Follow-up assessment and
treatment
IBS symptom severity score (0-
500) Abdominal pain score (0-100) IBS quality of life scale (0-100)
Mean % P value Mean % P value Mean % P value
Month 1
Psyllium −69 26 0.19 −8 19 0.95 5 7 0.95
Bran −61 22 0.47 −12 23 0.61 4 5 0.93
Placebo −49 18 NA −91 5 N A 3 4 N A
Month 2
Psyllium −69 26 0.92 −10 24 0.58 6 8 0.58
Bran −53 20 0.32 −11 20 0.63 5 7 0.85
Placebo −71 25 NA −14 26 NA 5 7 NA
Month 3
Psyllium −90 34 0.03 −14 32 0.79 7 10 0.79
Bran −58 22 0.61 −12 21 0.98 4 5 0.07
Placebo −49 18 NA −12 21 NA 4 6 NA
IBS=irritable bowel syndrome; NA=not applicable.
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Fig 2 | Proportion of patients with adequate relief of
symptoms each week (intention to treat analysis). *P<0.05
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differences between the treatment groups in abdom-
inal pain or health related quality of life. Bran showed
no clinically relevant benefit, and many patients
seemed not to tolerate bran.
Potential limitations
The selection process may have affected the generali-
sability of the results. A detailed comparison of rando-
mised patients with eligible but non-randomised
patients with irritable bowel syndrome (n=371) and
non-eligible patients with irritable bowel syndrome
(n=724) is reported elsewhere and showed that rando-
mised patients had a higher intensity of abdominal
pain, a higher consultation rate, and a longer history
of irritable bowel syndrome.
26
We allowed all patients with a diagnosis of irritable
bowel syndrome according to their general practi-
tioner to participate in the study in order to optimise
the applicability of the results to primary care clinical
practice. A sizeable proportion (61%) of our patients
did not fulfil the Rome II criteria. Subgroup analysis
showedaclinicallyrelevanteffectinboththecomplete
study population and patients who met the Rome II
criteria, although, as may be expected, the benefit
was somewhat greater in the second group. The
Rome criteria for irritable bowel syndrome have
been developed mainly for research purposes and are
infrequently used in primary care.
5-8
Successful blinding of dietary interventions in
research is difficult to achieve, but we took maximum
precautions to guarantee that the treatments looked
identical as regards packaging and content. Clinical
staff involved were kept blinded to treatment alloca-
tion throughout the study. However, in retrospect
approximately three quarters of patients correctly
guessed which treatment they were given. We have
no clear explanation for this. Partly, the appearance
orthetasteofthe treatmentmayhavebeenthe reason,
butpatientsmayalsohaverecognisedtheeffectofsolu-
ble or insoluble fibre supplements from previous
experience. For instance, a fibre supplement might
produce a greater sense of bloating than rice flour.
Forty per cent of the patients in this study stopped
participation before the final visit. The main reason
was that they felt worse when taking the fibre supple-
ment. Although this dropout rate is considerable, it is
comparabletothatinothertrialsofthisnature.
27-29The
motivation of patients to participate rapidly drops
when an intervention is cumbersome or time consum-
ing, especially when it does not lead to any immediate
effect or is difficult to tolerate. Obviously, a high drop-
out rate is going to contribute negatively to the overall
result of the study, especially when these patients are
classified as treatment failures. Although this “worst
casescenario”isthemostappropriatewayofanalysing
theeffectivenessoftreatment,itmayunderestimatethe
true effectiveness of fibre treatment.
20
The dropout rate was highest among those patients
randomised to bran, and this mainly occurred during
thefirstmonthoftreatment.Thiswasmainlyattributed
to worsening of symptoms of irritable bowel syn-
drome. This has also been reported in secondary
care,
3031anditissupportedbythefindingthatthenum-
ber of patients stopping treatment because of intoler-
ance was twice as high in the bran group as in the
psyllium or placebo group. Probably, those left in the
trial taking bran were a small subset of patients who
responded well to this supplement, as is also indicated
by the comparable adverse event rates reported in the
three groups.
Implications of findings
The results of this large scale trial in primary care sup-
port the addition of soluble fibre,such as psyllium,but
not bran as an effective first treatment approach in the
clinical management of patients with irritable bowel
syndrome.
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